Sign In

Jon Brassey

Director, Trip Database

Jon Brassey is the Director of TRIP Database Ltd, a position he has held since September 2001, spanning over 23 years.1 TRIP Database is a clinical search tool that focuses on evidence-based medicine.1

Professional Background

Brassey has a background in Applied Biology, having studied for his BSc at the University of the West of England. His expertise extends beyond his role at TRIP Database:

  • Data Science and AI: He has completed training in data science with a focus on artificial intelligence.4
  • Evidence Synthesis: Brassey is involved in initiatives related to evidence synthesis and has written about the value of information in this field.6
  • Bias in Health Studies: He is part of an initiative called "Catalogue of Bias" which addresses bias in health studies.5

Research Contributions

Brassey has been involved in significant research projects, particularly during the COVID-19 pandemic. He contributed to three WHO-funded systematic reviews on SARS-CoV-2 transmission causality, which were published on F1000R.3

Current Focus

As the director of TRIP Database, Brassey continues to work on improving clinical search tools and evidence-based medicine. He is also interested in the future of AI and its applications in healthcare, actively seeking input from industry experts and tech enthusiasts to shape the future of TRIP Database.2

Jon Brassey's LinkedIn profile (username: tripdatabase) serves as a platform for him to share updates about TRIP Database, discuss developments in evidence-based medicine, and engage with professionals in the fields of healthcare and technology.

Highlights

Oct 8 · linkedin

More experiments with LLMs/ChapGPT

This is really interesting. We’re busy looking at ways of using the power of LLMs to improve the user experience on Trip. One recent set of experiments relates to automated evidence reviews. While the following was semi-automatic it it is entirely possible to fully automate this. The review was exploring Brexpiprazole in schizophrenia and ran to three pages long. As part of the review we asked for a a conclusion and a clinical bottom line which are shown below.

Fully automated reviews, covering thousands of topics and updated daily - sounds pretty good to me.

Clinical bottom line: Brexpiprazole shows efficacy in treating schizophrenia with most randomized controlled trials reporting it as ‘effective’, especially at non-low doses. However, its effectiveness compared to certain other antipsychotics can vary, and further studies are needed to assess its cognitive benefits.

Conclusion: Brexpiprazole’s efficacy in treating schizophrenia has been studied in several contexts. A systematic review from 2022 has raised concerns about the efficacy of low-dose brexpiprazole as it was not found to be superior to placebo or standard-dose brexpiprazole. However, another systematic review from 2023 suggests that while brexpiprazole may be less effective than a specific dose of lurasidone (160 mg), it generally demonstrates comparable efficacy and safety to both lurasidone and cariprazine. Guidelines have noted some promising indications of brexpiprazole’s efficacy on cognitive performance in the context of second-generation antipsychotic compounds. Still, they have highlighted the need for further studies to accurately evaluate the extent of such benefits. Randomized controlled trials (RCTs) have provided mixed but mostly positive feedback. The majority of the RCTs mentioned rated the effectiveness of brexpiprazole as ‘effective’. Notably, these trials reported consistent improvements in PANSS scores, maintained improvements over time, and a favorable side-effect profile. Only one RCT gave a ‘neutral’ rating, mainly due to mixed findings and potential bias introduced by the known side effects of an active reference. Taking into account the weight typically given to systematic reviews and guidelines, the evidence suggests that brexpiprazole has some efficacy in treating schizophrenia, especially when not considering the low-dose. However, its effectiveness compared to some other antipsychotic compounds may vary, and further studies are recommended to determine its full range of benefits, especially in cognitive performance.

Mar 6 · linkedin

ChatGPT and Trip

Loads of hype around ChatGPT and other large language models. There's also a fair bit of - understandable - scepticism. But, not wanting to duck a challenge, we're keen to harness and experiment with these technologies. We have the funding and nearly there with the team. This should be interesting, informative and fun!

Related Questions

What are Jon Brassey's main responsibilities at TRIP Database Ltd?
How has Jon Brassey contributed to the development of the TRIP Database?
What is Jon Brassey's background in Applied Biology?
What projects has Jon Brassey worked on recently?
How has Jon Brassey's training in data science impacted his work?
Jon Brassey
Jon Brassey, photo 1
Jon Brassey, photo 2
Add to my network

Location

Greater Bristol Area, United Kingdom